Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KBP-5074 in healthy subjects and subjects with renal impairment
NCT02653014Phase 1Completed
- Sponsor
- KBP Biosciences
- Start
- Jul 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ocederenone (4 cohorts), sponsored by KBP Biosciences. Primary endpoint: Safety and tolerability at 69 days. Started Jul 2015; status: completed.
02
Drugs
ocederenone
Beyond the preview
Go deeper on NCT02653014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02653014.